Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030'"

With more than 90 Approved Products and over 240 Clinical Candidates, the Subcutaneous Biologics Market is Projected to Witness Commendable Growth across the Next Decade, Predicts Roots Analysis
By: Roots Anlaysis
Spread the Word
Listed Under



London City - London, Greater - England


LONDON - Oct. 4, 2018 - PRLog -- Roots Analysis has announced the addition of "'Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030'" report to its list of offerings.

Rupali Verma, the principal analyst, stated, "Close to 45% of the subcutaneously administrable biologics are monoclonal antibodies; these are followed by other types of protein-based therapeutics, including interferons, interleukins, hormones, enzymes and cytokines. Further, even certain vaccines, recombinant peptides and cell / gene therapies are other therapy types being evaluated for subcutaneous delivery. Moreover, ongoing technical advances have led to the development of innovative technology platforms designed to enable the delivery of highly viscous formulations as well."

The report presents opinions on several key aspects of the market. Among other elements, it includes:

1.  A detailed assessment of the current market landscape of commercially available biologics that are designed for delivery via the subcutaneous route, along with information on the developer(s), type of molecule, target indication / therapeutic area, approval year, dose strength, treatment regimen and available dosage forms. The study also includes comprehensive case studies on leading subcutaneous biologics, featuring details on annual sales, mechanisms of action, development histories, technology platforms (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).

2.  An in-depth analysis of the various subcutaneous biologics that are currently under clinical development, with information on the developer(s), phase of development, type of molecule, and target therapeutic area.

3.  A review of various innovative technology platforms that are used for the formulation of drugs for subcutaneous delivery, highlighting their key features and providing information on their developers, mechanisms of action and advantages. The study also includes an insightful three-dimensional analysis of the technology platforms that are presently engaged in developing drug formulations for subcutaneous delivery, comparing them based on pipeline strength (in terms of marketed / under development drugs based on the technology), supplier power (in terms of year of establishment and size of employee base) of the developer and a number of collaborations established related to the technology.

4.  A detailed benchmark analysis of technology providers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technology platforms, applicability to other types of molecules, and other possible modes of drug delivery.

5. Elaborate profiles of key technology providers, featuring an overview of the companies, a review of their proprietary technologies, mechanisms of action, key advantages, list of product candidates developed using the technology, recent developments related to the technology (funding and collaborations) and a comprehensive future outlook.

6. In-depth review of the most advanced and popular subcutaneous drug delivery systems, focused on large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants, providing information on their developer(s) and device specifications / features. Details of specific parameters captured for different device categories are mentioned as follows:

7. Large volume wearable injectors: Type of device (infusion pump and patch pump), type of dose delivered (continuous and bolus), volume of drug container / storage capacity (in mL), usability (disposable and reusable) and stage of development (commercialized and under development).

8. Autoinjectors: Type of drug container (syringe, cartridge and others), usability (disposable and reusable), mechanism of action (automatic, semi-automatic and manual), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).

9. Pen injectors: Usability (disposable and reusable), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).

10. Needle free injection systems: Type of technology (jet, spring and gas), usability (disposable and reusable) and drug volume delivered (in mL).

11. Prefilled syringes: Type of syringe (glass and plastic).

12. Drug reconstitution systems: Type of device (dual chambered systems and other novel systems), type of container (cartridge and others) and usability (disposable and reusable).

13. Implants: Type of material (silicone, titanium, polymers and others), target therapeutic indication, type of implant (biodegradable and non-biodegradable), treatment duration, type of drug delivered, dose strength and stage of development.

14. A comprehensive product competitiveness analysis of large volume wearable injectors and subcutaneous autoinjectors taking into consideration the supplier power (based on size of employee base) and product specifications.

A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall subcutaneous products market.

Verma further added, "Despite the various limitations associated with subcutaneous formulations, the field offers immense opportunities to pharmaceutical companies, device manufacturers and technology developers. Companies are also reformulating their intravenous drugs for subcutaneous administration for life cycle management and product differentiation purposes. The rising incidence of chronic clinical conditions (which are characterized by the need for frequent administration of medications) and continuous efforts of therapy / device developers in this field are anticipated to drive the growth in this market in the coming years."

The research covers detailed profiles and assesses product portfolios of the following companies:

1.  Adocia

2.  Ajinomoto Althea

3.  Arecor

4.  Ascendis Pharma

5.  Avadel Pharmaceuticals

6.  Camurus

7.   Halozyme Therapeutics

8.   MedinCell

9.   Xeris Pharmaceuticals

10. Serina Therapeutics

For additional details, please visit

or email

Media Contact
Gaurav Chaudhary
Posted By:*** Email Verified
Tags:Pharmaceutical, Biotechnology
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Roots Analysis PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share